2017
DOI: 10.1038/npp.2017.40
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Neuropsychiatric disorders such as schizophrenia are associated with cognitive impairment, including learning, memory and attention deficits. Antipsychotic drugs are limited in their efficacy to improve cognition; therefore, new therapeutic agents are required. Cannabidiol (CBD), the non-intoxicating component of cannabis, has anti-inflammatory, neuroprotective and antipsychotic-like properties; however, its ability to improve the cognitive deficits of schizophrenia remains unclear. Using a prenatal infection … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

9
72
2
1

Year Published

2018
2018
2022
2022

Publication Types

Select...
4
4

Relationship

2
6

Authors

Journals

citations
Cited by 107 publications
(84 citation statements)
references
References 87 publications
9
72
2
1
Order By: Relevance
“…There are over 113 known cannabinoids (Elsohly and Slade 2005), but the two most abundant natural derivatives are THC and cannabidiol (CBD). THC is responsible for the well-known psychoactive effects of cannabis consumption, but CBD, while nonintoxicating, also has therapeutic properties and is specifically being investigated as a treatment for both schizophrenia (Osborne et al 2017) and Alzheimer's disease (Watt and Karl 2017). Cannabis has traditionally been classified as having a drug ("marijuana") or hemp chemotype based on the relative proportion of THC to CBD, but types grown for psychoactive use produce relatively large amounts of both.…”
mentioning
confidence: 99%
“…There are over 113 known cannabinoids (Elsohly and Slade 2005), but the two most abundant natural derivatives are THC and cannabidiol (CBD). THC is responsible for the well-known psychoactive effects of cannabis consumption, but CBD, while nonintoxicating, also has therapeutic properties and is specifically being investigated as a treatment for both schizophrenia (Osborne et al 2017) and Alzheimer's disease (Watt and Karl 2017). Cannabis has traditionally been classified as having a drug ("marijuana") or hemp chemotype based on the relative proportion of THC to CBD, but types grown for psychoactive use produce relatively large amounts of both.…”
mentioning
confidence: 99%
“…is also required. In addition, similar to our rodent study of CBD effects on cognition in schizophrenia [31], most studies use either isolated CBD or combined THC and CBD. While this methodology enables investigators to attribute results to a specific compound, it may not be the optimal therapeutic approach as cannabis-derived plant molecules are thought to interact and produce a synergy that enhances therapeutic effects-termed the 'entourage effect'.…”
Section: Conclusion On the Use Of Cbd In Neurological Diseasementioning
confidence: 90%
“…We recently discovered that chronic CBD (10 mg/kg CBD, i.p., twice daily (b.i.d.)) treated cognitive impairment (learning, working and recognition memory) and social interaction deficits in a rat prenatal infection (poly I:C) model of schizophrenia-like phenotypes [31]. No behavioural changes were observed in healthy rats administered CBD and CBD did not cause weight gain side-effects [31].…”
Section: Schizophreniamentioning
confidence: 99%
See 1 more Smart Citation
“…Osborne and colleagues examined the effects of CBD in a rat Poly I:C model of maternal infection, which exhibit cognitive deficits and social interaction impairment [174]. In males, chronic CBD treatment in early adulthood rescued deficits in short term working memory in the novel object recognition test and rewarded t-maze, as well as social interaction deficits in Poly I:C rats, with no effects of CBD in non-Poly I:C treated rats [174]. Chronic CBD treatment in early adulthood attenuated Poly I:C-induced deficits in CB 1 receptor binding in the PFC as well as GAD67 binding in the hippocampus [175].…”
Section: Cannabinoids: Cbd Win Fatty Acid Amide Hydrolase Inhibitorsmentioning
confidence: 99%